These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 33922888)

  • 1. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
    Gomes FV; Grace AA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.
    Uliana DL; Lisboa JRF; Gomes FV; Grace AA
    Biochem Pharmacol; 2024 Oct; 228():116298. PubMed ID: 38782077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
    Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targets for drugs in schizophrenia.
    Stone JM; Pilowsky LS
    CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):265-72. PubMed ID: 17691983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of the Trace Amine Receptor, TAAR-1, in the Prefrontal Cortex of Individuals Affected by Schizophrenia.
    Imbriglio T; Alborghetti M; Bruno V; Battaglia G; Nicoletti F; Cannella M
    Schizophr Bull; 2024 Mar; 50(2):374-381. PubMed ID: 37897399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The search for novel antipsychotics: pharmacological and molecular targets.
    Sanger DJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):631-41. PubMed ID: 15584867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cytokine model of schizophrenia: emerging therapeutic strategies.
    Girgis RR; Kumar SS; Brown AS
    Biol Psychiatry; 2014 Feb; 75(4):292-299. PubMed ID: 24439555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Pharmacological Targets for the Treatment of Schizophrenia: A Literature Review.
    Ventriglio A; Bellomo A; Ricci F; Magnifico G; Rinaldi A; Borraccino L; Piccininni C; Cuoco F; Gianfelice G; Fornaro M; Delle Monache S; De Berardis D
    Curr Top Med Chem; 2021 Oct; 21(16):1500-1516. PubMed ID: 34218785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.
    Coyle JT; Balu D; Benneyworth M; Basu A; Roseman A
    Dialogues Clin Neurosci; 2010; 12(3):359-82. PubMed ID: 20954431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences.
    Aringhieri S; Carli M; Kolachalam S; Verdesca V; Cini E; Rossi M; McCormick PJ; Corsini GU; Maggio R; Scarselli M
    Pharmacol Ther; 2018 Dec; 192():20-41. PubMed ID: 29953902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine antagonist antipsychotics in diverted forensic populations.
    Cummings MA; Proctor GJ; Arias AW
    CNS Spectr; 2020 Apr; 25(2):128-135. PubMed ID: 31060635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.
    Perez SM; Lodge DJ
    Drug Des Devel Ther; 2014; 8():887-96. PubMed ID: 25061280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antipsychotics with no dopamine receptor blockade; promise or hype?].
    Vinkers CH
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis.
    Yilmaz Z; Zai CC; Hwang R; Mann S; Arenovich T; Remington G; Daskalakis ZJ
    Schizophr Res; 2012 Sep; 140(1-3):214-20. PubMed ID: 22795368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists.
    Peng A; Chai J; Wu H; Bai B; Yang H; He W; Zhao Y
    Neuropsychiatr Dis Treat; 2024; 20():607-620. PubMed ID: 38525480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.